ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision

ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision

Submitted by admin on June 2, 2024 - 2:48pm
Source: 
Fierce Biotech
News Tags: 
ASCO 2024
Jazz Pharmaceuticals
advanced biliary tract cancer
zanidatamab
Headline: 
ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision
snippet: 

As zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing long-term phase 2b data in advanced biliary tract cancer (BTC) for the HER2-targeted bispecific antibody.

Do Not Allow Advertisers to Use My Personal information